Trial Profile
A Randomised, Open-labelled, 4-period Crossover Trial Characterising Pharmacokinetics and Pharmacodynamics of Biphasic Insulin Aspart 30 Administered Once, Twice or Thrice Daily and Biphasic Human Insulin 30 Administered Once Daily in Subjects With Type 2 Diabetes.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Jan 2017
Price :
$35
*
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary) ; Insulin suspension isophane/insulin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Novo Nordisk
- 01 Aug 2009 Results were published in Diabetes Care.
- 23 Jan 2009 New trial record.